Prior to co-founding Medicxi, Michèle was a partner at Index Ventures for 10 years, having joined the firm in 2006. During that time she invested and continues to serve on the boards of a number of Index Life Sciences portfolio companies including Palladio Biosciences, Gadeta B.V, Epsilon 3 Bio Ltd. She also sits on the boards of Human Antibody Factory Ltd, Linguaflex and Diasome, one of the first investments of the Medicxi Growth fund. She was also a Director at OncoEthix (Sold to Merck Pharmaceuticals), Minerva Neurosciences (NASDAQ: NERV) and Aegerion (NASDAQ: AEGR).
Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/ Gencell/ Aventis International and Serono International.
She currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN). She also sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord.
Michèle completed her medical studies in France at Paris Ouest University.